索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]林颖,石琳.机械辅助循环治疗心力衰竭[J].国际心血管病杂志,2021,02:81-86.
点击复制

机械辅助循环治疗心力衰竭(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年02期
页码:
81-86
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
-
作者:
林颖; 石琳
100020 北京,首都儿科研究所附属儿童医院心内科
Author(s):
-
关键词:
终末期心力衰竭;  机械辅助循环;  人工心脏;  心室辅助装置
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.02.005
文献标识码:
-
摘要:
机械辅助循环设备是可以替代心脏功能、改善机体缺氧状态、促进器官功能恢复的人工器械。它可以减少心肌做功,显著提高终末期心力衰竭患者的生存率和生活质量。新型机械辅助循环设备具有侵入性小、微型化、耐久高、血流动力学效率高、血液相容性良好等特点。该文主要介绍常见人工心脏(包括HeartMateⅡ、Jarvik 2000、HeartMateⅢ、HeartWare、SynCardia等)以及一些新型设备(如 TORVAD、Carmat、RainHeart 和 BiVACOR 等)的原理、特点,并简要阐述目前机械辅助循环领域面临的挑战和未来的发展方向。
Abstract:
-

参考文献/References

[1] Kormos RL, Cowger J, Pagani FD, et al. The society of thoracic surgeons intermacs database annual report: evolving indications, outcomes, and scientific partnerships[J]. Ann Thorac Surg, 2019, 38(2):114-126.
[2] De BT, Mohacsi P, Gahl B, et al. The European registry for patients with mechanical circulatory support(EUROMACS)of the European Association for Cardio-thoracic Surgery(EACTS): second report[J]. Eur J Cardiothorac Surg, 2018, 53(2):309-316.
[3] Kinugawa K, Nishimura T, Toda K, et al. The second official report from Japanese registry for mechanical assisted circulatory support(J-MACS): first results of bridge to bridge strategy[J]. Gen Thorac Cardiovasc Surg, 2020, 68(2):102-111.
[4] 中国医师协会心力衰竭专业委员会, 国家心血管病专家委员会心力衰竭专业委员会, 中华心力衰竭和心肌病杂志编辑委员会. 经皮机械循环辅助临床应用及管理中国专家共识[J]. 中华心力衰竭和心肌病杂志, 2020, 3(3):145-158.
[5] Abott. Data on file. SJM-HM-1016-0032(3)[EB/OL].[2018-05-10]. https://www.heartmate.com/healthcare-provider/heartmate-ii-lvad
[6] Cogswell R, John R, Shaffer A. Right ventricular failure after left ventricular assist device[J]. Cardiol Clin, 2020, 38(2):219-225.
[7] Bartoli CR, Hennessy-Strahs S, Gohean J, et al. A novel toroidal-flow left ventricular assist device minimizes blood trauma: implications of improved ventricular assist device hemocompatibility[J]. Ann Thorac Surg, 2019, 107(6):1761-1767.
[8] Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events[J]. J Heart Lung Transplant, 2017, 36(10):1080-1086.
[9] Ono M, Sawa Y, Nakatani T, et al. Japanese multicenter outcomes with the HeartMate Ⅱ left ventricular assist device in patients with small body surface area[J]. Circ J, 2016, 80(9):1931-1936.
[10] Barac YD, Wojnarski CM, Junpaparp P, et al. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3[J]. J Thorac Cardiovasc Surg, 2020, 160(1):132-139.
[11] Domae K, Toda K, Matsuura R, et al. Jarvik 2000 with postauricular cable as destination therapy: first clinical case in Japan[J]. J Artif Organs, 2020, 23(1):89-92.
[12] Letsou GV, Anand J, Ogburn E, et al. Low incidence of pump-related infections in jarvik 2000 ventricular assist device recipients with a subcostal driveline exit site[J]. Tex Heart Inst J, 2019, 46(3):179-182.
[13] Kohno H, Matsumiya G, Sawa Y, et al. The jarvik 2000 left ventricular assist device as a bridge to transplantation: Japanese registry for mechanically assisted circulatory support[J]. J Heart Lung Transplant, 2018, 37(1):71-78.
[14] 管翔, 陈志远, 李庆国. 植入式心室辅助装置的研究进展[J]. 国际心血管病杂志, 2020, 47(2):76-80.
[15] Medtronic. Source data on file[EB/OL].[2019-07]. https://www.medtronic.com/us-en/healthcare-professionals/products/cardiac-rhythm/ventricular-assist-devices/heartware-hvad-system.html
[16] Mariani S, Hanke JS, Li T, et al. Device profile of the heartware HVAD system as a bridge-to-transplantation in patients with advanced heart failure: overview of its safety and efficacy[J]. Expert Rev Med Devices, 2019, 16(12):1003-1015.
[17] Slaughter MS, Pagani FD, Mcgee EC, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial[J]. J Heart Lung Transplant, 2013, 32(7):675-683.
[18] Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system[J]. J Am Coll Cardiol, 2011, 57(12):1375-1382.
[19] Strueber M, Larbalestier R, Jansz P, et al. Results of the post-market registry to evaluate the HeartWare left ventricular assist system(ReVOLVE)[J]. J Heart Lung Transplant, 2014, 33(5):486-491.
[20] Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure[J]. N Engl J Med, 2017, 376(5):451-460.
[21] Schmitto JD, Pya Y, Zimpfer D, et al. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study[J]. Eur J Heart Fail, 2019, 21(1):90-97.
[22] Netuka I, Sood P, Pya Y, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study[J]. J Am Coll Cardiol, 2015, 66(23):2579-2589.
[23] Krabatsch T, Netuka I, Schmitto JD, et al. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure—1 year results from the Ce mark trial[J]. J Cardiothorac Surg, 2017, 12(1):23.
[24] Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure[J]. N Engl J Med, 2017, 376(5):440-450.
[25] Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure[J]. Circulation, 2017, 135(21):2003-2012.
[26] Shah N, Agarwal V, Patel N, et al. National trends in utilization, mortality, complications, and cost of care after left ventricular assist device implantation from 2005 to 2011[J]. Ann Thorac Surg, 2016, 101(4):1477-1484.
[27] Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation[J]. N Engl J Med, 2004, 351(9):859-867.
[28] Cook JA, Shah KB, Quader MA, et al. The total artificial heart[J]. J Thorac Dis, 2015, 7(12):2172-2180.
[29] Dal Sasso E, Bagno A, Scuri S, et al. The biocompatibility challenges in the total artificial heart evolution[J]. Annu Rev Biomed Eng, 2019, 21:85-110.
[30] Mohacsi P, Leprince P. The CARMAT total artificial heart[J]. Eur J Cardiothorac Surg, 2014, 46(6):933-934.
[31] Latrémouille C, Duveau D, Cholley B, et al. Animal studies with the Carmat bioprosthetic total artificial heart[J]. Eur J Cardiothorac Surg, 2015, 47(5):e172-e179.
[32] Smadja DM, Susen S, Rauch A, et al. The carmat bioprosthetic total artificial heart is associated with early hemostatic recovery and no acquired von willebrand syndrome in calves[J]. J Cardiothorac Vasc Anesth, 2017, 31(5):1595-1602.
[33] Laumen M, Finocchiaro T, Cuenca E, et al. A novel total artificial heart for destination therapy: in-vitro and in-vivo study[J]. Biomed Tech(Berl), 2013, 58(Suppl 1):4373.
[34] Gräf F, Rossbroich R, Finocchiaro T, et al. Investigation of the durability of a diaphragm for a total artificial heart[J]. Artif Organs, 2016, 40(10):1016-1022.
[35] Ouweneel DM, De Brabander J, Karami M, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience[J]. Eur Heart J Acute Cardiovasc Care, 2019, 8(4):338-349.
[36] Bochaton T, Huot L, Elbaz M, et al. Mechanical circulatory support with the Impella○R LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: the IMPELLA-STIC randomized study[J]. Arch Cardiovasc Dis, 2020, 113(4):237-243.
[37] Schiller P, Hellgren L, Vikholm P. Survival after refractory cardiogenic shock is comparable in patients with Impella and veno-arterial extracorporeal membrane oxygenation when adjusted for SAVE score[J]. Eur Heart J Acute Cardiovasc Care, 2019, 8(4):329-337.
[38] Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device[J]. J Heart Lung Transplant, 2015, 34(12):1549-1560.
[39] Dangas GD, Kini AS, Sharma SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention(from the PROTECT Ⅱ randomized trial)[J]. Am J Cardiol, 2014, 113(2):222-228.
[40] O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT Ⅱ study[J]. Circulation, 2012, 126(14):1717-1727.
[41] Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock[J]. Am Heart J, 2006, 152(3):469-469.

备注/Memo

备注/Memo:
通信作者:石琳,E-mail:shilin9789@126.com
更新日期/Last Update: 2021-03-20